![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsors and Collaborators: |
National Institute on Drug Abuse (NIDA) University of Vermont |
---|---|
Information provided by: | National Institute on Drug Abuse (NIDA) |
ClinicalTrials.gov Identifier: | NCT00000220 |
The purpose of this study is to determine an optimal detoxification dose reduction schedule with buprenorphine.
Condition | Intervention | Phase |
---|---|---|
Opioid-Related Disorders |
Drug: Buprenorphine |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Double-Blind |
Official Title: | Gradual Vs. Rapid Buprenorphine Detoxification |
Ages Eligible for Study: | 33 Years to 43 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Please contact site for information.
United States, Vermont | |
Treatment Research Center | |
Burlington, Vermont, United States, 05401 |
Principal Investigator: | Warren Bickel, Ph.D. | University of Vermont |
Study ID Numbers: | NIDA-06969-2, R01-06969-2 |
Study First Received: | September 20, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00000220 |
Health Authority: | United States: Federal Government |
Buprenorphine Mental Disorders Substance-Related Disorders Disorders of Environmental Origin Opioid-Related Disorders |
Sensory System Agents Therapeutic Uses Narcotic Antagonists Physiological Effects of Drugs Central Nervous System Depressants Narcotics |
Peripheral Nervous System Agents Analgesics Central Nervous System Agents Pharmacologic Actions Analgesics, Opioid |